18PCombination treatment with the PARP inhibitor niraparib and chemotherapeutics in a preclinical model of KRAS/BRAF mutated colorectal cancer cell lines across the four consensus molecular subtypes. (23rd October 2018) - Vitiello, P P; Cardone, C; Ciardiello, D; Belli, V; Matrone, N; Borrelli, C; Poliero, L; De Falco, V; Giunta, E F; Vitale, P; Zanaletti, N; Tirino, G; et al.